Syringoma: Difference between revisions
No edit summary |
Simrat Sarai (talk | contribs) No edit summary |
||
Line 14: | Line 14: | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | |||
{{CMG}} {{AE}} {{Simrat}} | |||
{{SK}} Synonym 1; Synonym 2; Synonym 3 | |||
==Overview== | |||
==Historical Perspective== | |||
*[Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event]. | |||
*In [year], [gene] mutations were first identified in the pathogenesis of [disease name]. | |||
*In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name]. | |||
==Classification== | |||
*[Disease name] may be classified according to [classification method] into [number] subtypes/groups: | |||
:*[group1] | |||
:*[group2] | |||
:*[group3] | |||
*Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3]. | |||
==Pathophysiology== | |||
*The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3]. | |||
*The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway. | |||
*On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name]. | |||
*On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name]. | |||
==Causes== | |||
* [Disease name] may be caused by either [cause1], [cause2], or [cause3]. | |||
* [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s]. | |||
* There are no established causes for [disease name]. | |||
==Differentiating Syringoma from other Diseases== | |||
*Syringoma must be differentiated from other diseases such as: | |||
:*Acne Vulgaris | |||
:*Apocrine Hydrocystoma | |||
:*Basal Cell Carcinoma | |||
:*Colloid Milium | |||
:*Cowden Disease(Multiple Hamartoma Syndrome) | |||
:*Favre-Racouchot Syndrome(Nodular Elastosis With Cysts and Comedones) | |||
:*Granuloma Annulare | |||
:*Microcystic Adnexal Carcinoma | |||
:*Milia | |||
:*Sebaceous Hyperplasia | |||
:*Steatocystoma Multiplex | |||
:*Trichoepithelioma | |||
:*Tuberculosis | |||
:*Xanthelasma | |||
==Epidemiology and Demographics== | |||
* The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide. | |||
* In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location]. | |||
===Age=== | |||
*Patients of all age groups may develop [disease name]. | |||
*[Disease name] is more commonly observed among patients aged [age range] years old. | |||
*[Disease name] is more commonly observed among [elderly patients/young patients/children]. | |||
===Gender=== | |||
*[Disease name] affects men and women equally. | |||
*[Gender 1] are more commonly affected with [disease name] than [gender 2]. | |||
* The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1. | |||
===Race=== | |||
*There is no racial predilection for [disease name]. | |||
*[Disease name] usually affects individuals of the [race 1] race. | |||
*[Race 2] individuals are less likely to develop [disease name]. | |||
==Risk Factors== | |||
*Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4]. | |||
== Natural History, Complications and Prognosis== | |||
*The majority of patients with [disease name] remain asymptomatic for [duration/years]. | |||
*Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3]. | |||
*If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. | |||
*Common complications of [disease name] include [complication 1], [complication 2], and [complication 3]. | |||
*Prognosis is generally [excellent/good/poor], and the [1/5/10¬year mortality/survival rate] of patients with [disease name] is approximately [#%]. | |||
== Diagnosis == | |||
===Diagnostic Criteria=== | |||
*The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: | |||
:*[criterion 1] | |||
:*[criterion 2] | |||
:*[criterion 3] | |||
:*[criterion 4] | |||
===History=== | |||
*A positive family history of syringoma may be present. | |||
*The majority of patients with syringoma are asymptomatic. | |||
=== Symptoms === | |||
*[Disease name] is usually asymptomatic. | |||
*Symptoms of [disease name] may include the following: | |||
:*[symptom 1] | |||
:*[symptom 2] | |||
:*[symptom 3] | |||
:*[symptom 4] | |||
:*[symptom 5] | |||
:*[symptom 6] | |||
=== Physical Examination === | |||
*Patients with [disease name] usually appear [general appearance]. | |||
*Physical examination may be remarkable for: | |||
:*[finding 1] | |||
:*[finding 2] | |||
:*[finding 3] | |||
:*[finding 4] | |||
:*[finding 5] | |||
:*[finding 6] | |||
=== Laboratory Findings === | |||
*There are no specific laboratory findings associated with [disease name]. | |||
*A [positive/negative] [test name] is diagnostic of [disease name]. | |||
*An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name]. | |||
*Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3]. | |||
===Imaging Findings=== | |||
*There are no [imaging study] findings associated with [disease name]. | |||
*[Imaging study 1] is the imaging modality of choice for [disease name]. | |||
*On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3]. | |||
*[Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3]. | |||
=== Other Diagnostic Studies === | |||
*[Disease name] may also be diagnosed using [diagnostic study name]. | |||
*Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3]. | |||
== Treatment == | |||
=== Medical Therapy === | |||
*There is no treatment for [disease name]; the mainstay of therapy is supportive care. | |||
*The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2]. | |||
*[Medical therapy 1] acts by [mechanism of action1]. | |||
*Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration]. | |||
=== Surgery === | |||
*Surgery is the mainstay of therapy for [disease name]. | |||
*[Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name]. | |||
*[Surgical procedure] can only be performed for patients with [disease stage] [disease name]. | |||
=== Prevention === | |||
*There are no primary preventive measures available for [disease name]. | |||
*Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3]. | |||
*Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3]. | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Pick One of 28 Approved]] | |||
==Gallery== | ==Gallery== |
Revision as of 16:09, 22 April 2016
Syringoma | |
Syringomas highlighted by white circles. | |
ICD-10 | D23.9 |
ICD-9 | 216 |
ICD-O: | M8407/0 |
OMIM | 186600 |
DiseasesDB | 31358 |
MeSH | D018252 |
WikiDoc Resources for Syringoma |
Articles |
---|
Most recent articles on Syringoma |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Syringoma at Clinical Trials.gov Clinical Trials on Syringoma at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Syringoma
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Syringoma Discussion groups on Syringoma Directions to Hospitals Treating Syringoma Risk calculators and risk factors for Syringoma
|
Healthcare Provider Resources |
Causes & Risk Factors for Syringoma |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2] Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3
Overview
Historical Perspective
- [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
- In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
- In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].
Classification
- [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
- [group1]
- [group2]
- [group3]
- Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].
Pathophysiology
- The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
- The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
- On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
- On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
Causes
- [Disease name] may be caused by either [cause1], [cause2], or [cause3].
- [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
- There are no established causes for [disease name].
Differentiating Syringoma from other Diseases
- Syringoma must be differentiated from other diseases such as:
- Acne Vulgaris
- Apocrine Hydrocystoma
- Basal Cell Carcinoma
- Colloid Milium
- Cowden Disease(Multiple Hamartoma Syndrome)
- Favre-Racouchot Syndrome(Nodular Elastosis With Cysts and Comedones)
- Granuloma Annulare
- Microcystic Adnexal Carcinoma
- Milia
- Sebaceous Hyperplasia
- Steatocystoma Multiplex
- Trichoepithelioma
- Tuberculosis
- Xanthelasma
Epidemiology and Demographics
- The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
- In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].
Age
- Patients of all age groups may develop [disease name].
- [Disease name] is more commonly observed among patients aged [age range] years old.
- [Disease name] is more commonly observed among [elderly patients/young patients/children].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected with [disease name] than [gender 2].
- The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.
Race
- There is no racial predilection for [disease name].
- [Disease name] usually affects individuals of the [race 1] race.
- [Race 2] individuals are less likely to develop [disease name].
Risk Factors
- Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
Natural History, Complications and Prognosis
- The majority of patients with [disease name] remain asymptomatic for [duration/years].
- Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
- If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
- Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
- Prognosis is generally [excellent/good/poor], and the [1/5/10¬year mortality/survival rate] of patients with [disease name] is approximately [#%].
Diagnosis
Diagnostic Criteria
- The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
- [criterion 1]
- [criterion 2]
- [criterion 3]
- [criterion 4]
History
- A positive family history of syringoma may be present.
- The majority of patients with syringoma are asymptomatic.
Symptoms
- [Disease name] is usually asymptomatic.
- Symptoms of [disease name] may include the following:
- [symptom 1]
- [symptom 2]
- [symptom 3]
- [symptom 4]
- [symptom 5]
- [symptom 6]
Physical Examination
- Patients with [disease name] usually appear [general appearance].
- Physical examination may be remarkable for:
- [finding 1]
- [finding 2]
- [finding 3]
- [finding 4]
- [finding 5]
- [finding 6]
Laboratory Findings
- There are no specific laboratory findings associated with [disease name].
- A [positive/negative] [test name] is diagnostic of [disease name].
- An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
- Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
Imaging Findings
- There are no [imaging study] findings associated with [disease name].
- [Imaging study 1] is the imaging modality of choice for [disease name].
- On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
- [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
Other Diagnostic Studies
- [Disease name] may also be diagnosed using [diagnostic study name].
- Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
Treatment
Medical Therapy
- There is no treatment for [disease name]; the mainstay of therapy is supportive care.
- The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
- [Medical therapy 1] acts by [mechanism of action1].
- Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
Surgery
- Surgery is the mainstay of therapy for [disease name].
- [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
- [Surgical procedure] can only be performed for patients with [disease stage] [disease name].
Prevention
- There are no primary preventive measures available for [disease name].
- Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
- Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].
References
Gallery
-
Syringoma From Public Health Image Library (PHIL). [1]
-
Syringoma From Public Health Image Library (PHIL). [1]
-
Syringoma From Public Health Image Library (PHIL). [1]
-
Syringoma From Public Health Image Library (PHIL). [1]
-
Syringoma From Public Health Image Library (PHIL). [1]
-
Syringoma From Public Health Image Library (PHIL). [1]
-
Syringoma From Public Health Image Library (PHIL). [1]